Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
In vitro antiplatelet drug potency in MAFLD
NL-OMON51140Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jan 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of aspirin, clopidogrel and ticagrelor in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) (2 arms), sponsored by University Medical Center Groningen. Started Jan 2022; status: active, not recruiting.
02
Drugs
aspirinclopidogrelticagrelor
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NL-OMON51140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51140.